Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for reducing or removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.

Abstract: 2-Adamantyl- and 1-adamantyl-D/L-glycyl-L-alanyl-D-isoglutamine and their derivatives of the formulae ##STR1## wherein R stands for a hydrogen atom or a MurNAc group, and hydrochlorides thereof, a process for the preparation thereof and their use to obtain pharmaceuticals, which are particularly indicated for the treatment of viral diseases and tumors and/or immunomodulations in humans and animals.

Abstract: The present invention relates to a process for purifying Factor IX from an impure protein fraction containing Factor IX. The purification process comprises the steps of adding a solvent and a detergent to an impure protein fraction and incubating the solvent/detergent protein solution to inactivate any viral contaminants. Factor IX is purified from the solvent/detergent protein solution by chromatography on a sulfated polysaccharide resin without first removing the solvent and detergent prior to the purification on the sulfated polysaccharide resin. The Factor IX, purified by the process has a specific activity of at least 85 units/mg.

Abstract: Methods of enhancing the dewatering of gluten are disclosed. The methods comprise adding a nonionic surfactant to the wet gluten prior to dewatering, as in vacuum dewatering equipment. Particularly effective surfactants are oxyalkylated sorbiton R surfactants when R is monooleate, trioleate, monostearate, tristearate, monopalmitate and monolaurate.

Abstract: A novel glycosylated form of albumin designated EGA and isolated from biological fluids is further characterized by its cell growth promoting activity. A process of isolation of human or bovine glycosylated albumin is described. The EGA fractions have been identified by serological histochemical and biological assays as well as lectin reactivity. The growth-promoting effect of EGA is directed to various transformed cell lines and primary cells of mammalian origin. Hepatoma cells have been found to produce EGA, in vitro. Novel compositions of EGA containing media are provided for cell, tissue or organ culture.

Abstract: The present invention is to provide emulsion preparations for nasal administration containing calcitonins, which are safely and effectively administrated compared with the conventional calcitonin preparations. The emulsions are prepared by using a calcitonin as the active ingredient, an azacycloalkane derivative as the absorption promotor such as 1-[2-(decylthio)ethyl] azacyclopentan-2-one, and glycyrrhizic acid or its salt.

Abstract: The present invention provides a process for producing a .kappa.-casein glycomacropeptide comprising contacting milk raw materials containing the .kappa.-casein glycomacropeptide with an ion exchanger; collecting a fraction which does not adsorb on the ion exchanger; and concentrating and desalting the fraction to obtain the .kappa.-casein glycomacropeptide.

Abstract: A method for reducing the thrombogenicity of microvascular anastomoses in a warm blooded mammal comprising administering to said mammal at the site of said microvascular anastomoses contemporaneously with microvascular reconstruction of a small but inhibitory effective amount of TFPI.

Abstract: A collagen powder is obtained by wet-pulverizing a purified animal tissue consisting mainly of collagen in water at a collagen concentration of 1-30% by weight at a water temperature of not more than 37.degree. C. and a pH value of 2-8, tanning treating the pulverized tissue at a pH level of 2-7 with a polyvalent metal tanning agent to obtain a stabilized wet collagen product, dehydrating the wet collagen product at a pH level of 4-8, and then drying and pulverizing the dehydrated product into a powder. This powder can be used as an additive for modifying paints, artificial leathers, molding materials and the like based on synthetic resins such as thermoplastic resins. The materials obtained with this powder have an excellent appearance, feel, and moisture-absorbing and moisture-releasing properties.

Abstract: A method is disclosed for the prophylactic treatment of mammals at risk for acute renal failure, whether due to renal ischemia or nephrotoxic damage. This method involves administering to the mammal, before or at the time that the acute renal failure is expected to occur or is occurring, an effective amount of IGF-I. Preferably, the IGF-I is native-sequence, mature human IGF-I.

Abstract: A method for inhibiting the oxidation of a polypeptide in a liquid or semi-solid pharmaceutical or therapeutic preparation, the polypeptides having an amino acid sequence comprising at least one methionine residue, wherein the amino acid methionine is added in a sufficient amount to inhibit the oxidation of the methionine residue(s) to methionine sulfoxide.

Abstract: The use of pharmaceutical compositions comprising at least one antimalarial active substance and an interferon, preferably interferon-gamma (IFN-.gamma.), is disclosed. The pharmaceutical composition according to the invention are used in the treatment of clinical malaria.

Abstract: The invention relates to a method for a steroid resistant condition via administration of gamma interferon to a subject, such as a human, afflicted with the condition. The gamma interferon is administered in an amount sufficient to alleviate at least one parameter associated with the steroid resistant condition.

Abstract: The invention relates to a process of cross-linking collagen. This process is of the type comprising the formation of amide bonds by means of acylazide groups and is characterized in that the collagen is reacted with diphenylphosphorylazide. The process according to the invention makes it possible to simplify the collagen cross-linking process and to adjust the degree of cross-linking at discretion without introducing any cross-linking agent.

Abstract: The invention provides a thrombin coagulable protein concentrate,, the preparation thereof and the therapeutic use thereof. This concentrate has a fibrinogen content greater than 70% and a sufficient amount of endogenous Factor XIII. It may be solubilized at ambient temperature. Its preparation comprises at least one cold precipitation step with dilute ethanol and uses total plasma as a starting product. The concentrate of the invention makes it possible more particularly to obtain an injectable fibrinogen and a biological glue of high quality.

Abstract: Pharmaceutical compositions for controlling, by topical administration, localized bleeding in a patient, the composition comprising active PAI-1 protein in an amount effective to control the localized bleeding when topically administered, and a vehicle suitable for the topical administration, as well as methods and kits employing the same, are disclosed.

Abstract: A process for the preparation of an iron-free, pasteurized human transferrin is described and entails human transferrin being pasteurized in the presence of a complexing agent in solution, and the complexing agent being removed with the bound iron.This transferrin can be used as pharmaceutical or growth factor.

Abstract: Process for tanning a protein substance, in particular one of vegetable oin, such as oil seed proteins, characterized in that it includes treating the said protein substance with a dithiocarbamate type compound, partially degraded by a strong acid.

Abstract: A modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent. The cross-linking reagent is selected such that the .beta.-chains are cross-linked within the 2,3-diphosphoglycerate binding site and the linkage distance between the .beta.-chains is between about 5 to 9 angstroms. A method of preparing the modified hemoglobin and its use as a blood substitute or a plasma expander are also described.

Abstract: A composition for treating bone disorder or hypercalcemia of patients suffering from malignant tumors is disclosed. The composition of the present invention comprises an effective amount of interleukin-4 in a pharmaceutically acceptable carrier.